Stock Research for PSTI

PSTI

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

PSTI Stock Chart & Research Data

The PSTI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PSTI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


PSTI Due diligence Resources & Stock Charts

The PSTI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PSTI Detailed Price Forecast - CNN Money CNN View PSTI Detailed Summary - Google Finance
Yahoo View PSTI Detailed Summary - Yahoo! Finance Zacks View PSTI Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View PSTI Trends & Analysis - Trade-Ideas Barrons View PSTI Major Holders - Barrons
NASDAQ View PSTI Call Transcripts - NASDAQ Seeking View PSTI Breaking News & Analysis - Seeking Alpha
Spotlight View PSTI Annual Report - CompanySpotlight.com OTC Report View PSTI OTC Short Report - OTCShortReport.com
TradeKing View PSTI Fundamentals - TradeKing Charts View PSTI SEC Filings - Bar Chart
WSJ View Historical Prices for PSTI - The WSJ Morningstar View Performance/Total Return for PSTI - Morningstar
MarketWatch View the Analyst Estimates for PSTI - MarketWatch CNBC View the Earnings History for PSTI - CNBC
StockMarketWatch View the PSTI Earnings - StockMarketWatch MacroAxis View PSTI Buy or Sell Recommendations - MacroAxis
Bullish View the PSTI Bullish Patterns - American Bulls Short Pains View PSTI Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View PSTI Stock Mentions - StockTwits PennyStocks View PSTI Stock Mentions - PennyStockTweets
Twitter View PSTI Stock Mentions - Twitter Invest Hub View PSTI Investment Forum News - Investor Hub
Yahoo View PSTI Stock Mentions - Yahoo! Message Board Seeking Alpha View PSTI Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for PSTI - SECform4.com Insider Cow View Insider Transactions for PSTI - Insider Cow
CNBC View PSTI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PSTI - OTC Markets
Yahoo View Insider Transactions for PSTI - Yahoo! Finance NASDAQ View Institutional Holdings for PSTI - NASDAQ


Stock Charts

FinViz View PSTI Stock Insight & Charts - FinViz.com StockCharts View PSTI Investment Charts - StockCharts.com
BarChart View PSTI Stock Overview & Charts - BarChart Trading View View PSTI User Generated Charts - Trading View




Latest Financial News for PSTI


Free Technical Reports on Portola Pharma and Three Additional Biotech Equities
Posted on Thursday July 19, 2018

LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on PTLA sign up now at www.wallstequities.com/registration. WallStEquities.com revisits the Biotech space, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are the following equities: Pluristem Therapeutics Inc. (NASDAQ: PSTI), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Recro Pharma Inc. (NASDAQ: REPH), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN).


Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific
Posted on Monday July 09, 2018

Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that it has entered into a strategic collaboration with Thermo Fisher Scientific to advance fundamental knowledge of cell therapy industrialization and to improve quality control of the end-to-end supply chain. Together, the companies hope to transform cell therapy manufacturing into a large-scale, high capacity industry that will enable the production of millions of therapeutic doses of regenerative medicines.


Pluristem shares jump 2% on news of positive trial of treatment for radiation damage
Posted on Monday June 25, 2018

The Israeli company, which develops placenta-based cell therapies, said a study conducted with Fukushima Medical University of its PLX-R18 cells as a treatment for radiation damage to the gastrointestinal tract and bone marrow found that they significantly increase survival rates, preserve GI stem cells activity that improve the recovery of the system and prevent severe damage to the intestinal lining. The company said the cells may have potential as a multi-organ treatment for acute radiation syndrome, or ARS. "Lethality in ARS originates mainly from radiation-induced injuries to bone marrow and the GI tract, highlighting the importance of the study's purpose and results," Akihiro Inano, Ph.D. of Fukushima University, said in a statement.


Pluristem and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute Radiation Exposure
Posted on Monday June 25, 2018

Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, today reported positive data from studies conducted in collaboration with Fukushima Medical University evaluating PLX-R18 cells as a treatment for radiation damage to the gastrointestinal (GI) tract and bone marrow. Data from these studies showed that PLX-R18 cells significantly increase survival rates, preserve GI stem cells activity that enhance the recovery of the GI system and prevents severe damage to the intestinal lining, suggesting PLX-R18 potential as a multi-organ therapy for acute radiation syndrome (ARS). Under a Memorandum of Understanding (MOU) with Pluristem, Fukushima University, Fukushima Global Medical Science Center, has been developing targeted animal models of ARS and has been testing these models in studies to evaluate the efficacy of PLX-R18 in treating radiation damage to the GI tract and bone marrow of mice.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.